UCB SA (OTCMKTS:UCBJY – Get Free Report)’s stock price passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $57.90 and traded as high as $64.18. UCB shares last traded at $64.07, with a volume of 71,706 shares changing hands.
UCB Price Performance
The company has a 50-day moving average price of $57.90 and a 200 day moving average price of $47.06.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Recommended Stories
- Five stocks we like better than UCB
- 3 Warren Buffett Stocks to Buy Now
- United Airlines Soars on Earnings Beat
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- J.B. Hunt Hits the Skids: Lower Prices to Come
- What is a Secondary Public Offering? What Investors Need to Know
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.